←Palliative Care
Study register · detail Prospektive Real-World-Registerstudie · Palliative Care · 2018

Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer

Bar-Lev Schleider et al. ·European Journal of Internal Medicine Impact 3.3
Clear benefit GRADE Low 200 citations
Samplen = 2.970 Pat.
Duration6 months follow-up
EndpointSelf-reported symptom…
Blindingn.a.
DesignProspektive Real-World-Registerstudie
Cannabinoidvollspektrum
Key finding

95,9% of evaluable patients reported an improvement in their cancer-associated symptoms after 6 months of medical cannabis treatment.

Summary

Prospective real-world data on n=2970 cancer patients with medical cannabis (Israel 2015–2017); main symptoms: sleep disorders (78,4%), pain (77,7%, median 8/10), weakness (72,7%), nausea (64,6%), loss of appetite (48,9%). After 6 months follow-up, 95,9% of the remaining responders (n=1211/2056, 60,6%) reported an improvement in their condition, 3,7% no change, 0,3% worsening. Cannabis as palliative treatment well tolerated, effective and safe for symptom control in cancer patients.

P
PopulationCancer patients (various entities, 51,2% stage 4), n=2970, main symptoms: sleep problems, pain (median 8/10), nausea
I
InterventionMedical cannabis (Tikun Olam, various preparations), palliative, treatment program
O
OutcomeAfter 6 months, 95,9% of responders (n=1211) reported an improvement in their condition; 0,3% worsening
Confidence in the evidence
Low

The second of four GRADE levels, the effect estimate is of limited reliability.

Quality profile
Sample size ★★★★★
Blinding —
Effect size Clear benefit
Citations / year ★★★★★
Authors
Bar-Lev Schleider L, Mechoulam R, Lederman V et al.
DOI 10.1016/j.ejim.2018.01.023↗
Design: Prospektive Real-World-Registerstudie
Share
Indication
Further studies on Palliative Care
All studies →
S Hauser et al. · 2023 · The Cochrane database of systematic reviews
53 citations
Cannabis-based medicines and medical cannabis for adults with cancer pain.
No benefit demonstrated Meta-Analyse

Cochrane SR zu Cannabis-basierten Medikamenten bei Tumorschmerz (Erwachsene). Evaluiert Nutzen und Schäden vs. Placebo oder etablierte Analgetika; primäre Outcomes: ≤mild pain, PGIC much/very much improved, Withdrawals due to AE. Suche bis 26.01.2023, Einschlusskriterien: doppelblinde RCTs, ≥10 Teilnehmende pro Arm.

10.1002/14651858.cd014915.pub2 View study →
S Whiting et al. · 2015 · JAMA
2103 citations
Cannabinoids for Medical Use
Mixed

Umfassende SR über 79 RCTs (n=6.462) zu medizinischem Cannabis; moderate Evidenz für chronischen Schmerz (inkl. Krebs-assoziierter Schmerz) und MS-Spastik, schwache Evidenz für Chemotherapie-induzierte Übelkeit/Erbrechen, Appetitanregung bei HIV/AIDS und palliative Symptomkontrolle.

10.1001/jama.2015.6358 View study →
A Doppen et al. · 2022 · Journal of pain and symptom management
44 citations
Cannabis in Palliative Care: A Systematic Review of Current Evidence.
Mixed Systematic Review

Systematische Review zu Cannabis in der Palliativmedizin; k=52 Studien (20 RCTs, 32 nicht-randomisierte), n=4.786 Teilnehmende (Krebs n=4.491, Demenz n=43, AIDS n=235, Spastik n=16). Positive Behandlungseffekte (p<0.05) für einige Cannabis-Produkte bei Schmerz, Übelkeit/Erbrechen, Appetit, Schlaf, Fatigue bei Krebs-Patienten; Appetit/Agitation bei Demenz; Appetit/Übelkeit bei AIDS. Evidenzqualität durchgehend 'very low' oder 'low'. Meta-Analyse nicht durchführbar aufgrund Heterogenität der Produkte und Outcomes.

10.1016/j.jpainsymman.2022.06.002 View study →

The impediment to action advances action. — Marcus Aurelius